Lannett Company, Inc. (LCI)

Check out top investors' recommendation for LCI
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
N/A
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
N/A
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Lannett Company, Inc., together with its subsidiaries, develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States. The company manufactures solid oral dosage forms, including tablets, capsules, and topical and oral solutions; and is pursuing partnerships and research contracts for the development and production of ophthalmic, nasal, and injectable products. It offers products for various medical indications comprising glaucoma, parkinson’s disease, migraine headache, antibiotic, anesthetic, endometriosis, irritable bowels, obesity, congestive heart failure, antipsychotic, diuretic, pain management, thyroid deficiency, dryness of the mouth, epilepsy, gout, bronchospasms, hypertension, and gallstone. The company markets its products under the brand names of Diamox, Symmetrel, Fiorinal, Fiorinal w/ Codeine #3, Cleocin, Danocrine, Bentyl, Tenuate, Dospan, Lanoxin, Adoxa, Periostat, Prolixin, Microzide, Hydrodiuril, Dilaudid, Levoxyl/Synthroid, Loxitane, Roxicodone, Adipex-P, Fastin, Salagen, Mysoline, Benemid, Rifadin, Brethine, Dyazide, and Actigall. It also offers active pharmaceutical ingredients. Lannett Company, Inc. sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company was founded in 1942 and is based in Philadelphia, Pennsylvania.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Scott Henry Roth Capital Partners LLC Buy   Feb 07, '18     25.00  Feb 07, '19  N/A 
Elliot Wilbur Needham & Company Buy   Dec 01, '17       Dec 01, '18  N/A 
Scott Henry Roth Capital Partners LLC Buy   Aug 22, '17     27.00  Aug 22, '18  N/A 
Scott Henry Roth Capital Partners LLC Buy   Nov 04, '16     34.00  Nov 04, '17  N/A 
Scott Henry Roth Capital Partners LLC Buy   Mar 24, '16   18.31  27.50  Mar 24, '17  50.19% 
Matt Hewitt Craig-Hallum Capital Buy   Feb 04, '16   26.73    Feb 04, '17  N/A 
Scott Henry Roth Capital Partners LLC Buy   Feb 04, '16   26.73  40.00  Feb 04, '17  -25.36% 
Corey Davis Jefferies & Co. Buy   Feb 03, '16   24.33  28.00  Feb 03, '17  15.08% 
Scott Henry Roth Capital Partners LLC Buy   Sep 03, '15   55.81  68.00  Sep 03, '16  -43.04% 
Corey Davis Jefferies & Co. Buy   May 07, '15   53.04    May 07, '16  -66.42% 
Scott Henry Roth Capital Partners LLC Buy   Jan 30, '15   47.43    Jan 30, '16  -46.22% 
Steven Crowley Craig-Hallum Capital Buy   Nov 04, '14   56.25    Nov 04, '15  -16.66% 
Scott Henry Roth Capital Partners LLC Buy   Nov 04, '14   56.25  66.00  Nov 04, '15  17.33% 
Christopher Holterhoff Oppenheimer & Co. Buy   Oct 13, '14   41.31  53.00  Oct 13, '15  28.30% 
Christopher Holterhoff Oppenheimer & Co. Buy   Aug 28, '14   38.81  51.00  Aug 28, '15  31.41% 
Scott Henry Roth Capital Partners LLC Buy   Aug 25, '14   38.33    Aug 25, '15  20.38% 
Christopher Holterhoff Oppenheimer & Co. Buy   Jul 15, '14   47.09  52.00  Jul 15, '15  33.23% 
Scott Henry Roth Capital Partners LLC Buy   Jun 30, '14   49.62    Jun 30, '15  16.42% 
Christopher Holterhoff Oppenheimer & Co. Buy   Feb 07, '14   35.97  45.00  Feb 07, '15  44.01% 
Christopher Holterhoff Oppenheimer & Co. Buy   Oct 25, '13   23.72  29.00  Oct 25, '14  107.93% 
< previous12